 BOSTON, Oct. 01, 2021 GLOBE NEWSWIRE -- Sensei Biotherapeutics, Inc. NASDAQ: SNSE, an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA V-domain Ig suppressor of T cell activation product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer SITC being held in Washington, D.C. from November 10 - 14, 2021. These data are the first preclinical data to be presented by Sensei Bio in a scientific forum from the companys TMAb Tumor Microenvironment Activated biologics platform. 